Research Publications
The latest from Maverex.
Latest Posts
Find our peer-reviewed research publications across oncology, cardiovascular, infectious disease and much more.
Introduction of faecal calprotectin testing into the UK inflammatory bowel disease diagnostic pathway reduces environmental burden
Emily Archer Goode, Amy Swanston, John Bridgewood, Henry Swales, Antony Wright, Lindsay Nicholson
Value in Health, 27S329
P6 Projected increase of the clinical, economic, societal, and environmental burdens of chronic kidney disease in Switzerland: insights from Impact-CKD
Campbell-James, T., Pruijm, M., Hall, A., Rosemann, T., Rodriguez, C. V., Zara, A., Priest, S., Nicholson, L., Hubbert, L., Rao, N., +3 more... (2024).
Value in Health,27(12 Supplement), S2 - S2. https://doi.org/10.1016/j.jval.2024.10.008
Adherence to NICE guidelines for chronic obstructive pulmonary disease can improve patient outcomes and reduce carbon footprint when compared with current clinical practice
Swanston A, Hubbert L, Shrivastava M ...
Value in Health, 27S350
Challenges and Solutions to Estimating Environmental Impact in Health Technology Assessment
ISPOR Europe 2023: Poster Session: 4. 14 November 2023. Poster Session Time: 15:30-18:30. Discussion Period: 16:00-17:00
Reducing carbon footprint by switching to reusable soft mist inhalers
Janson C, Platz JH, Soulard S, Langham S, Nicholson L, Hartgers-Gubbels ES. Reducing carbon footprint by switching to reusable soft mist inhalers. ERJ Open Res 2023;9(3):00543-2022.
Reusable soft mist inhalers have an improved carbon footprint compared with dry powder inhalers and pressurised metered-dose inhalers
Janson C, Hernando Platz J, Soulard S, Langham S, Nicholson L, Hartgers-Gubbels E. Reusable soft mist inhalers have an improved carbon footprint compared with dry powder inhalers and pressurised metered-dose inhalers (HSD2). Poster presented at ISPOR Europe; 6-9th November 2022; Vienna: Austria, 2022
Treatment with dual and triple therapy in chronic obstructive pulmonary disease in line with current guidelines reduces the carbon footprint
Janson C, Hernando Platz J, Soulard S, Langham S, Nicholson L, Hartgers-Gubbels E. Treatment with dual and triple therapy in chronic obstructive pulmonary disease in line with current guidelines reduces the carbon footprint (MT40). Poster presented at ISPOR Europe; 6-9th November 2022; Vienna: Austria, 2022
Is evidence on environmental impact included in health technology assessment and does it influence decision-making?
Hubbert L, Embleton N, Wright A, Nicholson L. Is evidence on environmental impact included in health technology assessment and does it influence decision-making? (HTA56). Poster presented at ISPOR Europe; 6-9th November 2022; Vienna: Austria, 2022
